Every carbapenem on the market requires a needle. Tebipenem would be the first you can swallow. The FDA decides June 18.
What Carbapenems Are
Carbapenems are the antibiotics you use when everything else fails. They are the broadest-spectrum beta-lactams available — active against most Gram-negative pathogens including ESBL-producing Enterobacterales, the resistant organisms that increasingly define complicated urinary tract infections. Imipenem, meropenem, ertapenem, doripenem — all IV-only. All require hospitalization.
That requirement isn't pharmacological. It's historical. Carbapenems were developed for severe, hospital-acquired infections. No one designed an oral formulation because the patients who needed carbapenems were already in beds.
Until the resistance crisis made that assumption obsolete.
The Problem Tebipenem Solves
Complicated UTI is a hospitalization engine. Not because cUTI is inherently dangerous — clinical cure rates exceed 90% regardless of drug — but because the oral antibiotics that work against resistant organisms are running out. Fluoroquinolone resistance in E. coli exceeds 30% in many regions. Trimethoprim-sulfamethoxazole resistance is climbing. Patients who would otherwise go home stay in hospital beds receiving IV carbapenems for infections that respond to oral treatment — if an oral option existed.
Tebipenem pivoxil hydrobromide is that option. An oral prodrug, rapidly converted to the carbapenem tebipenem in plasma. Broad-spectrum activity against ESBL-producing Enterobacterales. Developed by Meiji in Japan (approved there since 2009 for pediatric use), licensed to Spero Therapeutics, then to GSK after Spero's near-collapse.
The First Rejection
This is tebipenem's second attempt. The first NDA, filed on ADAPT-PO Phase 3 data, received a Complete Response Letter in June 2022.
The rejection wasn't about the drug. It was about how patients were counted.
The Micro-ITT Dispute
ADAPT-PO's protocol specified a microbiological intent-to-treat (micro-ITT) population with a noninferiority margin of -12.5%. The trial showed tebipenem 58.8% vs. ertapenem 61.6% — within margin by Spero's pre-specified analysis.
The FDA conducted its own reclassification of the micro-ITT population. Under the FDA's criteria, noninferiority was not met. The agency concluded the data were "insufficient to support approval."
Spero cut 75% of its workforce. The oral carbapenem was dead.
The Redesign
GSK licensed tebipenem in 2023 and funded a new trial. PIVOT-PO was designed to remove every ambiguity that killed ADAPT-PO:
| ADAPT-PO (2022) | PIVOT-PO (2025) | |
|---|---|---|
| Patients | 868 | 1,690 |
| Comparator | IV ertapenem | IV imipenem-cilastatin |
| NI margin | -12.5% | -10% |
| Overall response | 58.8% vs 61.6% | 58.5% vs 60.2% |
| Treatment difference | -2.8% | -1.3% (CI: -7.5, 4.8) |
| Clinical cure | — | 93.5% vs 95.2% |
| ESBL+ efficacy | disputed | comparable |
| Outcome | CRL | Stopped early for efficacy |
Nearly double the patients. Tighter noninferiority margin. Different comparator (imipenem-cilastatin instead of ertapenem — a harder test). And the IDMC stopped it early because the data were clear enough.
The overall response rates look similar to ADAPT-PO — 58.5% vs 60.2% — but the confidence interval (-7.5% to 4.8%) sits entirely within the -10% margin. Clinical cure was 93.5% vs 95.2%. No new safety signals. Diarrhea and headache, all mild or moderate.
The Stewardship Question
Here is the tension that no approval can resolve: carbapenems are last-resort antibiotics because resistance to them is still rare. Carbapenem-resistant Enterobacterales (CRE) kill roughly 1,100 Americans per year. Making carbapenems easier to use — a pill instead of an IV — could accelerate CRE selection pressure.
The counter-argument is that tebipenem's indication is narrow (cUTI only), its spectrum is defined, and the alternative isn't "no carbapenem" — it's "IV carbapenem in a hospital bed for a week." The drug doesn't expand who gets carbapenems. It changes where they get them.
This is the argument the FDA is evaluating. Not just efficacy. Not just safety. Whether the stewardship profile of an oral carbapenem is acceptable in an era of rising resistance. QIDP and Fast Track designations suggest the agency sees the need. No advisory committee was convened — which, for a first-in-class antibiotic, is a notable signal.
The Binary
GSK submitted the NDA in December 2025. PDUFA is June 18, 2026.
Bull case
PIVOT-PO cleanly addresses every ADAPT-PO deficiency. No AdCom scheduled. QIDP + Fast Track. Trial stopped early for efficacy. ESBL+ subgroup consistent. The prior CRL was about statistics, not the drug — and the statistics are now unambiguous.
Bear case
Stewardship concerns could trigger labeling restrictions or REMS. The FDA that issued the 2022 CRL was unusually rigorous on this NDA — a new review team may raise new questions. Manufacturing or CMC issues (the ghost haunting every 2026 PDUFA) could surface.
Affected tickers: GSK (sponsor, commercialization rights), SPRO (licensor, $175M+ in milestones tied to approval and sales). SPRO is the more binary play — approval triggers near-term milestones on a $56M cash position.
Cross-reference: Amurai tracks tebipenem in the context of antimicrobial resistance — the stewardship tension between treating resistant infections now and preserving carbapenem efficacy for the future. PACCARB meets June 16. The AMR policy landscape is shifting around this approval.